The market for obesity medicines has spent the past several years chasing a single question: how much weight can a drug take off, and at what dose? Novo Nordisk's CagriSema has been one of the most closely watched answers. The therapy is a once-weekly subcutaneous fixed dose combination of the long acting amylin analogue cagrilintide and the GLP-1 receptor agonist semaglutide, designed to act on two separate appetite pathways at the same time. Until this month, nearly all of the late stage evidence for the combination came from regimens built around the maximum 2.4 mg/2.4 mg dose that anchors the company's REDEFINE programme.
Dose selection is not a housekeeping detail in this drug class. Higher doses of GLP-1 based therapies generally buy more weight loss, but they also bring more gastrointestinal upset, more titration steps and, for some patients, a reason to stop treatment altogether. Novo Nordisk has therefore been testing whether a lower fixed dose pair can keep most of the efficacy while making the first months of treatment easier to tolerate.
The trial built to answer it is REDEFINE 9. It enrolled 309 adults without diabetes who had a body mass index of at least 30 kg/m2, or at least 27 kg/m2 with one or more obesity related complication. The study ran at 24 sites across Canada, France, Germany, the United Kingdom and the United States, lasted 68 weeks, and randomised participants 2:1:2:1 to CagriSema 1.7 mg/1.7 mg, matching placebo, CagriSema 1.0 mg/1.0 mg or matching placebo, with all groups receiving nutrition and physical activity counselling.
Novo Nordisk announced on November 14, 2026 that the two lower dose regimens produced estimated average body weight loss of 20.7 percent and 21.0 percent at 68 weeks, against 2.0 percent for pooled placebo. The data were presented at ObesityWeek 2026 in Washington, DC, and published the same day in The Lancet Diabetes & Endocrinology. REDEFINE 9 is the first phase 3 trial in weight management to test CagriSema below the 2.4 mg/2.4 mg maximum dose used elsewhere in the programme, which makes the readout a question about range rather than about peak potency.
Key Facts
On the efficacy estimand, the 1.7 mg/1.7 mg group lost an estimated 20.7 percent of body weight and the 1.0 mg/1.0 mg group lost 21.0 percent, compared with 2.0 percent on pooled placebo. The estimated treatment differences were 18.8 and 19.0 percentage points, with a p value below 0.0001. Under the treatment regimen estimand, which accounts for participants who stopped taking the drug, the figures were 19.4 percent, 18.6 percent and 4.6 percent respectively. Mean baseline body weight across the trial was 109.5 kg, and the three arms contained 104, 103 and 102 participants.
At least 5 percent weight loss was achieved by 95.1 percent of participants on 1.7 mg/1.7 mg and 96.3 percent on 1.0 mg/1.0 mg, versus 33.4 percent on placebo. At least 20 percent weight loss was reached by 51.3 percent and 48.3 percent respectively, against 2.7 percent with placebo. Waist circumference, a confirmatory secondary endpoint, fell by 17.2 cm and 17.5 cm in the two active arms, compared with 3.6 cm on placebo.
Safety looked consistent with the class. Securities.io reported on November 14, 2026 that adverse events occurred in 99 percent of treated participants on 1.7 mg/1.7 mg, 95 percent on 1.0 mg/1.0 mg and 91 percent on placebo, most of them mild to moderate gastrointestinal events, with no deaths. Permanent discontinuation because of adverse events was 2.9 percent and 4.9 percent in the active arms, identical to 4.9 percent on placebo. Of the 309 people randomised, 291 completed the study and 254 were still on treatment at week 68.
The Lancet Diabetes & Endocrinology reported on November 14, 2026 that the study was designed as a multicentre, randomised, double blind within dose level, placebo controlled, parallel group phase 3b trial, with block randomisation in blocks of six through a web based system. Both active regimens started at 0.25 mg of each component and escalated over 12 weeks for the higher pair and eight weeks for the lower pair. The paper lists Sean Wharton of the Department of Medicine at the University of Toronto and the Wharton Medical Clinic in Burlington, Ontario as lead author. The publication carries PMID 43033821 and doi 10.1016/S2213-8587(26)00275-5, and Novo Nordisk funded the study and supplied the drugs.
Novo's chief scientific officer, Martin Holst Lange, said the results add to the understanding of CagriSema across doses. The company also confirmed that CagriSema remains unapproved in the United States, where a New Drug Application filed in December 2025 covers the higher 2.4 mg/2.4 mg regimen for weight management, with a decision expected in the fourth quarter of 2026.
Analysis
Two lower dose regimens landing at roughly 21 percent look like a free lunch, and it is not quite that. The trial was not powered to compare the two CagriSema arms with each other, so the 0.3 percentage point gap between 20.7 percent and 21.0 percent carries no statistical weight. Securities.io noted the same limitation on November 14, 2026, pointing out that the numerical similarity of the two regimens does not establish superiority or equivalence.
What this really means is that the interesting result is not a dose ranking but a flattened dose response curve. In this class, cutting the dose usually costs efficacy, and here it largely did not, at least within the range tested. The placebo adjusted effect stayed essentially stable while the titration schedule shortened from 12 weeks to eight. That pattern matters more than the decimal places, because it suggests the combination's dual mechanism may be doing enough work at lower exposure that higher doses mostly add side effects rather than additional benefit.
The tolerability data support that reading without proving it. Discontinuation due to adverse events was 2.9 percent at 1.7 mg/1.7 mg and 4.9 percent at 1.0 mg/1.0 mg, the latter matching placebo exactly, and the overall adverse event rates of 99 percent, 95 percent and 91 percent show how common mild gastrointestinal symptoms remain even at reduced doses. A drug that nearly everyone reports something about, yet from which almost nobody withdraws, is one physicians can work with.
There is also a disclosure history to keep straight. Novo had already put roughly 21 percent efficacy estimand weight loss for the 1.0 mg/1.0 mg regimen into its September 21, 2026 Capital Markets Day materials. The new contribution is therefore the complete, peer reviewed, two dose dataset with safety and secondary endpoints, not a first glimpse of the efficacy figure.
Why It Matters
For clinicians, the practical consequence is optionality. Obesity treatment has been drifting toward a model in which patients start low, escalate slowly and stop if the side effects outweigh the benefit. A lower fixed dose pair that holds close to the top dose effect gives physicians a legitimate place to pause the escalation, particularly for patients sensitive to gastrointestinal effects or managing several other conditions.
For Novo Nordisk, the readout strengthens a franchise that is approaching a regulatory hinge. Ad-Hoc-News reported on November 15, 2026 that the company's shares rose 2.7 percent in the session as it presented at ObesityWeek and filed for a sickle cell therapy. The same report noted that Novo's third quarter 2026 results, published on November 4, showed adjusted operating profit of DKK 31.7 billion, up 27 percent at constant currencies, with full year guidance ranging from a 2 percent decline to 2 percent growth in currency neutral terms for both adjusted sales and adjusted operating profit.
For the wider obesity field, the trial is a reminder that the next phase of competition may be about fit rather than raw percentage points. At ObesityWeek, Novo also presented two post hoc analyses of the phase 3 REDEFINE 1 trial of CagriSema 2.4 mg/2.4 mg, in which participants who responded early averaged 25.4 percent weight loss at 68 weeks. The company's own framing, reported by Ad-Hoc-News on November 15, 2026, is that this work is hypothesis generating rather than confirmatory, because early responders are a selected subgroup and post hoc analyses do not carry the weight of a prespecified primary endpoint.
Next Up
The immediate focus is the US Food and Drug Administration, which is reviewing the 2.4 mg/2.4 mg regimen for weight management after the December 2025 filing. Novo expects a decision in the fourth quarter of 2026. Whatever the agency decides will set the commercial baseline against which these lower dose findings are eventually read, since the REDEFINE 9 regimens are not themselves the subject of the pending application.
Beyond that, Novo has a crowded calendar. It has submitted Etavopivat, a once daily investigational therapy for sickle cell disease, to both the FDA and the European Medicines Agency, with decisions expected in 2027, and it won European Union approval of FREHEMGO for routine bleeding prevention in haemophilia A. The company also committed USD 200 million to the World Diabetes Foundation for diabetes prevention and care in low and middle income countries across 2027 to 2036.
Comments (0)
Log in or sign up to leave a comment.
No comments yet. Be the first to share your thoughts.